Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Sell
29
JANX Quote, Financials, Valuation and Earnings
Last price:
$56.14
Seasonality move
:
84.76%
Day range:
$55.61 - $57.00
52-week range:
$7.79 - $71.71
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
220.32x
P/B ratio:
4.49x
Volume:
378K
Avg. volume:
1.3M
1-year change:
431.13%
Market cap:
$2.9B
Revenue:
$8.1M
EPS (TTM):
-$1.16
Analysts' Opinion
-
Consensus RatingJanux Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Janux Therapeutics has an estimated upside of 63.23% from its current price of $56.14.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $56.14.
Fair Value
-
According to the consensus of 9 analysts, Janux Therapeutics has 63.23% upside to fair value with a price target of -- per share.
JANX vs. S&P 500
-
Over the past 5 trading days, Janux Therapeutics has underperformed the S&P 500 by -8.52% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Janux Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Janux Therapeutics revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Janux Therapeutics reported revenues of $439K.
Earnings Growth
-
Janux Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Janux Therapeutics reported earnings per share of -$0.51.
Enterprise value:
2.3B
EV / Invested capital:
3.49x
Price / LTM sales:
220.32x
EV / EBIT:
--
EV / Revenue:
175.36x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-60.50x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-10.65%
Net Income Margin (TTM):
-463.91%
Return On Equity:
-11.37%
Return On Invested Capital:
-11.37%
Operating Margin:
-8164.47%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $7.4M | $8.5M | $13M | $2.5M | $439K | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$62.3M | -$75.1M | -$86M | -$15.8M | -$35.8M | |
| EBITDA | -$61.8M | -$73.3M | -$83.9M | -$15.3M | -$35.3M | |
| Diluted EPS | -$1.46 | -$1.48 | -$1.16 | -$0.25 | -$0.51 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $389.6M | $344.3M | $355.2M | $666.3M | |
| Total Assets | -- | $391.1M | $375.8M | $386.9M | $695M | |
| Current Liabilities | -- | $12.5M | $16.3M | $14.5M | $17.2M | |
| Total Liabilities | -- | $14.3M | $44.2M | $37.9M | $38.9M | |
| Total Equity | -- | $376.8M | $331.5M | $348.9M | $656.1M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$41.5M | -$52.6M | -$37M | -$11.7M | -$2.2M | |
| Cash From Investing | $67.2M | -$53.9M | -$280.8M | -$61.5M | $12.7M | |
| Cash From Financing | $473K | $58.9M | $327.4M | $56.6M | $1.6M | |
| Free Cash Flow | -$47.1M | -$56M | -$37.8M | -$12.2M | -$2.3M | |
JANX
Sector
Market Cap
$2.9B
$45.6M
Price % of 52-Week High
78.29%
45.55%
Dividend Yield
0%
0%
Shareholder Yield
-13.46%
-0.74%
1-Year Price Total Return
431.13%
-31.35%
Beta (5-Year)
--
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$57.97
200-day SMA
Buy
Level
$47.04
Bollinger Bands (100)
Buy
Level
42.26 - 56.22
Chaikin Money Flow
Sell
Level
-16M
20-day SMA
Sell
Level
$57.52
Relative Strength Index (RSI14)
Sell
Level
49.37
ADX Line
Buy
Level
13.52
Williams %R
Buy
Level
-88.9206
50-day SMA
Buy
Level
$54.22
MACD (12, 26)
Buy
Level
1.23
25-day Aroon Oscillator
Buy
Level
12
On Balance Volume
Neutral
Level
23.9M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (8.0858)
Buy
CA Score
(Annual)
Level (0.4651)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (0.635)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.
Stock Forecast FAQ
In the current month, JANX has received 8 Buy ratings 1 Hold ratings, and 0 Sell ratings. The JANX average analyst price target in the past 3 months is --.
-
Where Will Janux Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Janux Therapeutics share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Janux Therapeutics?
Analysts are divided on their view about Janux Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Janux Therapeutics is a Sell and believe this share price will drop from its current level to --.
-
What Is Janux Therapeutics's Price Target?
The price target for Janux Therapeutics over the next 1-year time period is forecast to be -- according to 9 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is JANX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Janux Therapeutics is a Buy. 8 of 9 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of JANX?
You can purchase shares of Janux Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Janux Therapeutics shares.
-
What Is The Janux Therapeutics Share Price Today?
Janux Therapeutics was last trading at $56.14 per share. This represents the most recent stock quote for Janux Therapeutics. Yesterday, Janux Therapeutics closed at $56.14 per share.
-
How To Buy Janux Therapeutics Stock Online?
In order to purchase Janux Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
